Dr. Reddy’s Laboratories Ltd which can be found using ticker (RDY) now have 3 analysts in total covering the stock. The consensus rating is pointing to ‘Strong_Buy’. The range between the high target price and low target price is between 67 and 60.6 calculating the average target price we see $62.87. Given that the stocks previous close was at $55.24 this indicates there is a potential upside of 13.8%. The day 50 moving average is $54.05 and the 200 moving average now moves to $53.77. The market capitalization for the company is $9,315m. Visit the company website at: https://www.drreddys.com
The potential market cap would be $10,602m based on the market consensus.
Dr. Reddy’s Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), Proprietary Products, and Others segments. The company’s Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations. This segment also engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. Its Proprietary Products segment focuses on the research and development of differentiated formulations. The Others segment engages in developing therapies in the fields of oncology and inflammation. The therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. The company has a collaboration, license, and option agreement with Curis, Inc. to discover, develop, and commercialize small molecule antagonists for immuno-oncology and precision oncology targets. Dr. Reddy’s Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of 20.85, revenue per share of 1429.43 and a 9.49% return on assets.
